Key takeaways
- The South African label covers moderate-to-severe androgen-sensitive acne and/or hirsutism, including these symptoms in people with PCOS. SAHPRA-approved Diane-35 information.
- For acne, the local label places it where topical treatment or systemic antibiotics are not considered appropriate. South African indication.
- Diane-35 also provides hormonal contraception, but should not be combined with another hormonal contraceptive. Local product information.
- The EMA found a higher venous clot risk than with levonorgestrel-containing combined pills, while retaining a role for appropriate acne and hirsutism treatment. EMA benefit-risk review.
Acne that returns around the menstrual cycle can make a hormonal treatment appealing, especially when unwanted facial hair is part of the picture. But “a pill for PCOS” is too broad a description of Diane-35.
It combines cyproterone acetate, which counters androgen effects, with ethinylestradiol, an oestrogen. The reason to choose it should be specific: which symptoms need treatment, what has already been tried and whether its risk profile fits the person taking it.
Does Diane-35 treat PCOS itself?
It can treat particular androgen-related symptoms in someone with PCOS; it is not a cure for the whole condition.
The South African indication explicitly includes patients with PCOS who need treatment for the acne or hirsutism described in the label. That is more precise than claiming it corrects every hormonal, metabolic or fertility concern associated with PCOS. Local prescribing information.
It is also a contraceptive. If pregnancy is the goal, that changes the treatment conversation rather than making Diane-35 a fertility medicine.
For facial hair specifically, our eflornithine guide explains a different, local treatment approach. For persistent acne, the isotretinoin article examines another option with a different set of benefits and precautions.
When is a hormonal acne treatment worth considering?
It is one option among several, not the inevitable next step for every breakout.
The American Academy of Dermatology’s acne guidance includes combined oral contraceptives alongside topical treatments, antibiotics and other systemic therapies. The presence of several supported options is a reason to match treatment to the acne and the patient, not to rank everything by how “strong” it sounds. AAD acne guideline.
| Main treatment goal | Useful question |
|---|---|
| Persistent inflammatory acne | Are topical or antibiotic options suitable, and what has already failed? |
| Acne with unwanted facial hair | Would an anti-androgen approach address both concerns? |
| Contraception without acne or hirsutism | Is a contraceptive chosen for that purpose a better fit? |
| Trying to conceive | What non-contraceptive plan addresses the symptoms? |
The local label’s wording and a personal risk assessment remain important even when an overseas guideline supports the wider treatment class.
How should the blood-clot warning be interpreted?
The relative increase is real, but it does not mean a clot is likely for every user.
The EMA review estimated venous thromboembolism risk at about 1.5 to 2 times that with levonorgestrel-containing combined oral contraceptives. That comparison is with a particular group of pills, not with every contraceptive. A relative increase also does not provide an individual’s absolute chance of a clot. EMA review.
The excess risk is greatest during the first year and when restarting after a break. Previous clots, family history, smoking, migraine with aura, surgery and periods of immobility are among the issues to discuss before treatment. The benefit-risk decision can change over time, so continuing treatment deserves review rather than automatic renewal. EMA assessment.
New one-sided leg pain or swelling, unexplained shortness of breath or chest pain, or sudden neurological symptoms require urgent medical attention.
What should be checked before starting or changing packs?
Confirm the exact product, the contraceptive plan and any interacting medicines.
Different presentations can have different pack instructions. Follow the supplied leaflet and prescribing advice rather than a generic online pill calendar. Do not add another hormonal contraceptive to Diane-35. South African product information.
Regulatory note
South Africa, checked 8 September 2026: The cited South African Diane-35 professional information lists it as Schedule 4. Its PCOS wording concerns treatment of specified androgen-related symptoms, not a general PCOS cure.
Do and don’t
Do: Discuss both the skin problem and your contraception or pregnancy plans.
Don’t: Dismiss new clot symptoms, combine hormonal contraceptives or assume that acne improvement removes the need for follow-up.
